2023 Oncology & Precision Medicine Conference

Professor Sir Munir Pirmohamed is David Weatherall Chair of Medicine at the University of Liverpool, and a Consultant Physician at the Liverpool University Hospital Foundation NHS Trust. He is Director of the Centre for Drug Safety Sciences, Director of the Wolfson Centre for Personalised Medicine and Director of HDR North.

He is an inaugural National Institute for Health and Care Research Senior Investigator, Fellow of the Academy of Medical Sciences in the UK, and Chair of the Commission on Human Medicines. He is also a non-executive director of NHS England, President of Association of Physicians GB&I and medical trustee for the British Heart Foundation. He is the Past-President of the British Pharmacological Society.

He was awarded a Knights Bachelor in the Queen’s Birthday Honours in 2015.

His research focuses on:

• personalised medicine
• clinical pharmacology
• drug safety.

Joanne M. Hackett is Vice President and Head of Genomic and Precision Medicine at IQVIA and previously was the Chief Commercial Officer at Genomics England.
 
Dr Hackett is a clinical academic, entrepreneur, investor, and a strategic, creative visionair with global experience spanning successful start-ups to Fortune 500 companies. Aside from her curious passion for life and positivity, Joanne is known for building innovation, driving personalised medicine and leading through fast paced, complex changing ecosystems and integrations. Joanne's goal is to contribute to bringing the world novel, cost effective and simple health care solutions, and she is particularly keen on building the case for prevention, open science and citizen genomics. She has extensive global experience across academic, business and clinical institutions, and enjoys sharing her experiences with the Boards she sits on as well as companies she provides strategic advice to.
 
Joanne has been publicly recognised for her relentless pursuit of revolutionising healthcare and has been named one of the top six Influential Leaders in Healthcare by CIO Look, the Accenture Life Science Leader of the year, Freshfields Top 100 Most Influential Women, One HealthTech Top 70 Women in the NHS, Pharmaceutical Market Europe’s 30 women leaders in UK healthcare and BioBeat Top 50 Women in Biotech Award. Joanne believes in human courage and perseverance against the odds, and demonstrates that positive change, whether in a company or in one’s personal life, can be carved out from even the greatest of trials. As a believer of ‘health = wealth’, Joanne is an internationally known yoga instructor.

David Sebag-Montefiore is the Audrey and Stanley Burton Professor of Clinical Oncology at the University of Leeds and an honorary Clinical Oncologist at Leeds Teaching Hospitals NHS Trust.

After completion of undergraduate medical training at St Bartholomew’s Hospital Medical School, University of London, and clinical oncology training in at St Bartholomew’s, Middlesex and Mount Vernon Hospitals, he moved to Leeds as a Consultant in Clinical Oncology at Leeds Teaching Hospitals NHS Trust.

David is the Director of the Leeds CRUK Radiotherapy Centre of Excellence (RadNet) and a Clinical Director at the Leeds CRUK Clinical Trials Unit. He was awarded the Royal College of Radiologists Rohan Williams medal in 1989, and the Gold Medal in 2019 in recognition of his outstanding contribution to the field of clinical oncology nationally and internationally.

His research interests focus on improving outcomes for patients with rectal and anal cancer including radiotherapy and clinical trials. He leads a portfolio of practice changing and innovative gastrointestinal cancer clinical trials with a focus on rectal and anal cancer including the MRC CR07, CRUK ACT2, CRUK ARISTOTLE and CRUK PLATO ACT3, 4 and 5 trials. He is previous chair of the National Cancer Research Institute (NCRI) radiotherapy research group (CTRad), the CTRad Proton Beam Clinical Trial Strategy Group and Cancer Research UK’s Clinical Trials Awards and Advisory Committee.

Professor Caroline Dive CBE, PhD, FBPhS, FMedSci
Upon completing her PhD studies, Professor Caroline Dive moved to Aston University's School of Pharmaceutical Sciences in Birmingham where she established her own group studying mechanisms of drug induced tumour cell death, before moving to The University of Manchester to continue this research. Caroline was awarded a Lister Institute of Preventative Medicine Research Fellowship before joining the Cancer Research UK Manchester Institute (CRUK MI) in 2003. Currently, she is Interim Director of the Institute and Director of the CRUK Cancer Biomarker Centre, with research spanning tumour biology, preclinical pharmacology, biomarker discovery, biomarker assay validation and clinical qualification to regulatory standards, bioinformatics, biostatistics and most recently, digital clinical trials.

Caroline was awarded the Pasteur-Weizmann/Servier International Prize in 2012 for her Biomarker Research, the AstraZeneca Prize for Women in Pharmacology in 2016 and was presented with the 2019 Heine H. Hansen Lectureship Award by the International Association for the Study of Lung Cancer (IASLC). She is an elected Fellow of the Academy of Medical Sciences (2015), Fellow of the British Pharmacological Society (2012) and Fellow of the European Academy of Cancer Sciences (2011). In 2017, Caroline was awarded Commander of the Order of the British Empire (CBE) for her services to cancer research. Most recently, she became an elected member of EMBO (2020), received the first inaugural Johann Anton Merck Award in recognition for exceptional contributions to the field of preclinical oncology (2020), and was the recipient of the Mary J. Matthews Pathology/Translational Distinguished Service Award by IASLC (2021). Caroline was the President of the European Association for Cancer Research (2020 – 2022).